The health technology assessment agency for England and Wales, NICE, has confirmed its view that Janssen-Cilag's (Johnson & Johnson) Stelara (ustekinumab) should be a treatment option for some patients with severe plaque psoriasis.
The health technology assessment agency for England and Wales, NICE, has confirmed its view that Janssen-Cilag's (Johnson & Johnson) Stelara (ustekinumab) should be a treatment option for some patients with severe plaque psoriasis.
Its second version of draft guidance repeats the main conclusions of an earlier draft: Stelara is clinically and cost-effective for...
Create an account to read this article
Already a subscriber?
Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?
Paying €90m upfront for rights to generalized pustular psoriasis drug.
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
Multi-blockbuster falls short in a giant cell arteritis study.
The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.
A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.
As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
